Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of GS-9256 plus GS-9190 with or without ribavirin in treatment‑naive chronic hepatitis C genotype 1
2009-013690-18Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Nov 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of GS-9256 and tegobuvir in hepatitis C virus infection (3 arms), sponsored by Gilead Sciences. Primary endpoints: Rapid virologic response (RVR) at Day 28 and Change in HCV RNA from baseline. Started Nov 2009; status: completed.
02
Drugs
GS-9256tegobuvir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2009-013690-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013690-18.